Administration of CXCL10-Fc and CXCL9-Fc limits melanoma growth while selecting subtypes of effector and cytotoxic CD4+ and CD8+ T cells with an IFN-γhigh signature, further limiting tumor growth. Here, CXCL9 is linked to melanoma.